MARKET

AQST

AQST

Aquestive Therapeutics
NASDAQ
4.075
+0.055
+1.37%
Opening 10:40 03/16 EDT
OPEN
4.030
PREV CLOSE
4.020
HIGH
4.080
LOW
3.990
VOLUME
228.10K
TURNOVER
--
52 WEEK HIGH
7.55
52 WEEK LOW
2.120
MARKET CAP
497.33M
P/E (TTM)
-5.2004
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AQST last week (0309-0313)?
Weekly Report · 10h ago
Aquestive Therapeutics: Post-CRL Risk, Timeline, And Valuation
Seeking Alpha · 3d ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQST
Barchart · 4d ago
Aquestive Therapeutics Files Initial Beneficial Ownership Statement for Chief Medical Officer Matthew J. Greenhawt
Reuters · 5d ago
Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval
Seeking Alpha · 5d ago
Rosen Law Firm Urges Aquestive Therapeutics, Inc. (NASDAQ: AQST) Stockholders to Contact the Firm for Information About Their Rights
Barchart · 6d ago
Aquestive Therapeutics grants CMO 75,000 restricted stock units and 50,000 stock options under 2022 Inducement Plan
Reuters · 03/09 20:01
AQUESTIVE THERAPEUTICS ANNOUNCES GRANT OF INDUCEMENT AWARD PURSUANT TO NASDAQ LISTING RULE 5635(C)(4)
Reuters · 03/09 20:01
More
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.

Webull offers Aquestive Therapeutics Inc stock information, including NASDAQ: AQST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AQST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AQST stock methods without spending real money on the virtual paper trading platform.